Enanta Pharmaceuticals Overview
Valuation check: ENTA's ROE is -62.56%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow-62.56%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Enanta Pharmaceuticals (ENTA) currently reports a ROE of -62.56%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Enanta Pharmaceuticals's ROE history and peer comparisons.
Enanta Pharmaceuticals's ROE of -62.56% is higher than the Healthcare sector average of -100.59%. That is roughly 37.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Enanta Pharmaceuticals's current -62.56% should be judged against Healthcare norms (sector average: -100.59%) and against ENTA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -62.56%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Enanta Pharmaceuticals, and consider following ENTA for alerts when major investors trade the stock.
Enanta Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -62.56% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ENTA with unrelated industries.
